Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cellular

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    « Previous 1  2  3  4  5  6  7  Next»
    Study title:
    Active substance: Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content)
    Study summary document link (including results):
    View full study record
    Document reference: 47296
    Study title: Open, controlled, randomized phase III clinical study to assess the immunogenicity and reactogenicity of TdcP-IPV vaccine vs DTacP + OPV in 6 years old children previously immunized with 4 doses of DTwcP and OPV from 2 months of age.
    Active substance: Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content)
    Study summary document link (including results):
    View full study record
    Document reference: 47295
    Study title: Safety and Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (TdcP) Vaccine Compared to Tetanus and Diphtheria Toxoids Adsorbed (Td) in Adolescents and Adults 11-64 Years of Age
    Active substance: Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content)
    Study summary document link (including results):
    View full study record
    Document reference: 47291
    Study title: Safety and Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (TdcP) Vaccine Compared to Tetanus and Diphtheria Toxoids Adsorbed (Td) in Adolescents and Adults 11-64 Years of Age
    Active substance: Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content)
    Study summary document link (including results):
    View full study record
    Document reference: 47292
    Study title: Safety and Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (TdcP) Vaccine Compared to Tetanus and Diphtheria Toxoids Adsorbed (Td) in Adolescents and Adults 11-64 Years of Age
    Active substance: Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content)
    Study summary document link (including results):
    View full study record
    Document reference: 47293
    Study title: Safety of four acellular pertussis combination vaccines (Infantrix-IPV, Boostrix, Covaxis and repevax) given a booster dose to six-year-old Finnish children
    Active substance: Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content)
    Study summary document link (including results):
    View full study record
    Document reference: 47294
    Study title: Pulmonary embolism: A fatal complication of arterial chemoembolization for advanced hepatocellular carcinoma.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39907
    Study title: Successful left hepatectomy for hepatocellular carcinoma in a child after transcatheter arterial chemoembolization: Report of a survival.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39945
    Study title: The role and limitation of living donor liver transplantation for hepatocellular carcinoma.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39896
    Study title: A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B(12) binding capacity in a young Japanese female.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39909
    Study title: Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39927
    Study title: Hepatocellular carcinoma after transcatheter hepatic arterial embolization: A histopathologic study of 84 resected cases.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39940
    Study title: Hepatocellular carcinoma and portal vein invasion: Results of treatment with transcatheter oily chemoembolization.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39935
    Study title: Hepatocellular carcinoma outcomes based on indicated treatment strategy.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39931
    Study title: An open, controlled, randomised, clinical study to assess the immunogenicity and safety of HEXAVAC® administered to healthy infants who received hepatitis B vaccine (RECOMBIVAX H-B®) at birth
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Vaccine, Adsorbed and Haemophilus influenzae type b conjugate vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47189
    Study title: Assessment of the Immunogenicity and Safety of the Sanofi Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™), Administered at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants Included in Two Study Groups Receiving the Hepatitis B Monovalent Vaccine Either at 0, 6, and 14 Weeks of Age or at 6, 10, and 14 Weeks of Age.
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Vaccine, Adsorbed and Haemophilus influenzae type b conjugate vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47187
    Study title: Clinical Safety study of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) in Healthy Children and in Healthy Infants in the People’s Republic of China
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Vaccine, Adsorbed and Haemophilus influenzae type b conjugate vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41322
    Study title: Immunogenicity and Safety of a Booster Dose of Aventis Pasteur’s DTacPIPV// PRP~T Combined Vaccine (Pentavac™/Pentaxim™) in 18-24 Months Old Children Primed with DTacP-HB-IPV-PRP~T Combined Vaccine (Hexavac™) in the Study A3R31
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Vaccine, Adsorbed and Haemophilus influenzae type b conjugate vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47188
    Study title: Immunogenicity and Safety of the Aventis Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants in India
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Vaccine, Adsorbed and Haemophilus influenzae type b conjugate vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41321
    Study title: Placebo controlled randomized study of haemophilus influenzae type b capsular polysaccharide tetanus conjugate vaccine (PRP-T) associated or combined with diphtheria- tetanus- pertussis vaccine (DTP) in two month old infants
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Vaccine, Adsorbed and Haemophilus influenzae type b conjugate vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47153
    Study title: Comparative Safety and lmmunogenicity Study of Diphtheria, Tetanus, Acellular Pertussis, Poliomyelitis Vaccine (DTacP-IPV) and Diphtheria, Tetanus, Whole-cell Pertussis, Poliomyelitis Vaccine (TETRACOQ) Given As a Second Booster to 4- to 7-Year-Old Children
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41420
    Study title: Comparative Safety and lmmunogenicity Study of Diphtheria,Tetanus, Acellular Pertussis, Poliomyelitis vaccine (DTacP-IPV) and Diphtheria, Tetanus, Poliomyelitis Vaccine (D.T. Polio) Administered as a Booster in Children Aged 8 to 12 years
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41421
    Study title: Comparative study of acellular and whole cell pertussis vaccines combined with diphtheria, tetanus and inactivated poliomyelitis type 1, 2, 3 vaccines in healthy infants (primary-immunisation and booster)
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41413
    Study title: Comparative study of the safety and immunogenicity of a Diphtheria Tetanus Acellular Pertussis and a Diphtheria Tetanus Whole Cell Pertussis vaccine in Senegalese infants
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41411
    Study title: Comparative, randomised, double-blind safety and immunogenicity study of the Mérieux two-component acellular pertussis vaccine and the Mérieux one-component vaccine in healthy adult volunteers
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41406
    Study title: Dose response study of a Diphtheria, Tetanus, acellular Pertussis (DTacP) vaccine in 3-month-old children
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41407
    Study title: Evaluation of the PMSV. Diphtheria, Tetanus, Acellular Pertussis Vaccine (DTacP) in Infants, during a NlAlD Multicenter Acellular Pertussis Trial. Comparative Study Between PMSV. DTacP and Two Conventional Whole Cell DTP Vaccines
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41409
    Study title: Immunogenicity and reactogenicity of two dosages of acellular pertussis vaccine compared with whole-cell pertussis vaccine at primary (2, 4 and 6 months of age) and booster (15-24 months and 4-6 years of age) immunisation
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41408
    Study title: Large Scale Safety Study of the DTacP-IPV (Acellular Tetracoq) Vaccine, Administered in Combination (one injection site) or in Association (two injection sites) with Haemophilus influenzae type b Vaccine (Act-HIB) for Primary and Booster immunisation.
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41415
    Study title: Open, Randomised, Comparative Trial of the lmmunogenicity and Safety of two Immunisation Schedules (2-34 months and 24-6 months of age) using Diphtheria, Tetanus, Acellular Pertussis, Polio (DTacP-IPV) Vaccine mixed with Haemophilus influenzae type b (Act-HI B) Vaccine.
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41417
    Study title: Randomised Double-Blind Study of the Relative Efficacy and Safety of a DT Acellular Pertussis Vaccine with Respect to a DTP Whole-Cell Vaccine Among Children of Rural Senegal (Niakhar)
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41412
    Study title: Randomised, Open Trial of the lmmunogenicity and Safety of Diphtheria, Tetanus, Acellular Pertussis (DTacP) Vaccine Associated or Combined with Act-HIB Vaccine Given at 2-4-6 or 3-4-5 Months in Healthy Infants
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41418
    Study title: Safety and immunogenicity of a Diphtheria, Tetanus, acellular Pertussis, enhanced inactivated trivalent Poliovirus vaccine administered separately or combined with Haemophilus influenzae type b vaccine, to healthy Chilean Infants
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41416
    Study title: Safety and Immunogenicity of P.M. SV. Diphtheria, Tetanus, Acellular Pertussis, Polio (DTacP-IPV) Vaccine Given Mixed or Separately with Haemophilus influenzae type b (Act-HIBB) Vaccine, as a Primary Series. Comparison of Three Lots of DTacP-IPV Vaccine Given Combined or Separately with Act-HIB.
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41414
    Study title: Study of Safety and lmmunogenicity After Simultaneous Administration of DTacP-IPV Il Act-HIB Vaccine and ROR VAX (MMR) Vaccine in 14- to 16-Month-Old Toddlers
    Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed.
    Study summary document link (including results):
    View full study record
    Document reference: 41419
    Study title: DTPa-HBV-IPV-020
    Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41517
    Study title: DTPa-HBV-IPV-055 Infanrix hexa
    Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41510
    Study title: DTPa-HBV-IPV-063
    Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41511
    Study title: DTPa-HBV-IPV-070
    Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41512
    Study title: DTPa-HBV-IPV-075
    Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41513
    « Previous 1  2  3  4  5  6  7  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 08:27:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA